ARCHIVES

Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

Republican Congress To Shift Priorities, But Cancer May Get New Opportunities

November 18, 1994

NCAB Votes To Return P01 Review To Pre-1987 System, Two-Tier Review

May 14, 1993

NCI Advisory Groups To Be Cut By One-Third

April 22, 1977

Report on Carcinogens Lists Estrogen, UV Light, Wood Dust;

January 10, 2003

Varmus Discusses Grant Policy, Changes in Congress and Ebola

December 12, 2014

Scientists Tell Panel: Peer Review Need Improving, Available Funds Should Be Spread Over More Grants

April 30, 1982